Relmada Therapeutics (RLMD) FCF Margin (2012 - 2013)
Relmada Therapeutics (RLMD) posted quarterly FCF Margin of 493.19% for Q4 2013, down 56285.0% year-over-year from N/an in Q4 2012, and down 293.28% quarter-over-quarter from 125.4% in Q1 2013.
Powered by 
Analysis
Relmada Therapeutics (RLMD) FCF Margin (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has reported FCF Margin for 2 consecutive years, with 493.19% the latest figure, recorded in Q4 2013.
- In Q4 2013, FCF Margin fell 56285.0% year-over-year to 493.19%; the TTM figure through Nov 2013 stood at 249.81% (changed N/A YoY), while the FY2013 annual figure was 196.12%, down 10086.0% from the prior year.
- FCF Margin retreated to 493.19% in Q4 2013 per RLMD's latest filing, from 125.4% in the prior quarter.
- Across five years, FCF Margin topped out at 69.66% in Q4 2012 and bottomed at 496.5% in Q2 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Nov 30, 2013 | -493.19% |
| Feb 28, 2013 | 327.32% |
| Nov 30, 2012 | 69.66% |
| Aug 31, 2012 | -220.73% |
| May 31, 2012 | -496.50% |